Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer

JAMA Oncology

Volumn 2, Issue 12, 2016, Pages 1598-1606

  Wyatt, Alexander W ^a   Azad, Arun A ^b,c   Volik, Stanislav V ^a   Annala, Matti ^d   Beja, Kevin ^a   McConeghy, Brian ^a   Haegert, Anne ^a   Warner, Evan W ^a   Mo, Fan ^a   Brahmbhatt, Sonal ^a   Shukin, Robert ^a   Bihan, Stephane Le ^a   Gleave, Martin E ^a   Nykter, Matti ^d   Collins, Colin C ^a   Chi, Kim N ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MONASH UNIVERSITY   (Australia)

^d Institute of Biosciences and Medical Technology   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; AR PROTEIN, HUMAN; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; DNA; ENZALUTAMIDE; PHENYLTHIOHYDANTOIN; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

AGED; ANALOGS AND DERIVATIVES; BLOOD; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; GENOMICS; HUMAN; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN RECEPTOR ANTAGONISTS; BETA CATENIN; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RETINOBLASTOMA BINDING PROTEINS; TREATMENT OUTCOME; UBIQUITIN-PROTEIN LIGASES;

EID: 85013175347     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0494     Document Type: Article

References (45)

1. Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014; 65(2):289-299.
2. Beer TM, Armstrong AJ, Rathkopf DE, et al.; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433.
3. de Bono JS, Logothetis CJ, Molina A, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
4. Ryan CJ, Smith MR, de Bono JS, et al.; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
5. Scher HI, Fizazi K, Saad F, et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
6. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med. 2015;7(7):878-894.
7. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23-29.
8. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802-1807.
9. Chi K, Hotte SJ, Joshua AM, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015;26(10):2044-2056.
10. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem. 2014;47(10-11): 889-896.
11. Quek SI,Wong OM, Chen A, et al. Processing of voided urine for prostate cancer RNA biomarker analysis. Prostate. 2015;75(16):1886-1895.
12. Antonarakis ES, Lu C,Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038.
13. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6(254):254ra125.
14. Azad AA, Volik SV,Wyatt AW, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(10):2315-2324.
15. Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7(312):312re10.
16. Scher HI, Halabi S, Tannock I, et al.; Prostate Cancer Clinical TrialsWorking Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol. 2008;26(7):1148-1159.
17. Azad AA, Leibowitz-Amit R, Eigl BJ, et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014;74(15):1544-1550.
18. Robinson D, Van Allen EM,Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228.
19. Lorente D, Mateo J, Zafeiriou Z, et al. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol. 2015;12(1):37-47.
20. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013; 63(5):920-926.
21. Grasso CS,Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-243.
22. Cooper CS, Eeles R,Wedge DC, et al.; ICGC Prostate Group. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015;47(4):367-372.
23. Gundem G, Van Loo P, Kremeyer B, et al.; ICGC Prostate UK Group. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520 (7547):353-357.
24. Hong MK, Macintyre G,Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015;6:6605.
25. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324 (5928):787-790.
26. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3 (9):1020-1029.
27. Schwartz S,Wongvipat J, Trigwell CB, et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell. 2015;27(1):109-122.
28. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res. 1998;58(12):2520-2523.
29. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013;110(50):20224-20229.
30. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697-1708.
31. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-892.
32. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18(5):R183-R196.
33. Li Y, Hwang TH, Oseth LA, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012;31(45):4759-4767.
34. Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582-591.
35. van de Wijngaart DJ, Molier M, Lusher SJ, et al. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem. 2010;285(7):5097-5105.
36. Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6): 1273-1280.
37. Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer. 2014;111 (12):2248-2253.
38. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994;59(10):597-602.
39. Krishnan AV, Zhao XY, Swami S, et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002;143(5):1889-1900.
40. Munuganti RS, Hassona MD, Leblanc E, et al. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem Biol. 2014;21(11):1476-1485.
41. Dalal K, Roshan-Moniri M, Sharma A, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer [published correction appears in J Biol Chem. 2014;289(49):33877]. J Biol Chem. 2014;289(38):26417-26429.
42. Lalonde E, Ishkanian AS, Sykes J, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15(13):1521-1532.
43. de Leeuw R, Berman-Booty LD, Schiewer MJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795-807.
44. Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonicalWnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351-1356.
45. Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3(9):1030-1043.